Get started
Author

Rachel Koelmeyer

Observed names: Koelmeyer, Rachel, R Koelmeyer, R. Koelmeyer, R.L. Koelmeyer, RL Koelmeyer, Rachel Koelmeyer (5347271), Rachel L Koelmeyer, Rachel L. Koelmeyer
Institution: Monash University
Observed institutions: Royal Children's Hospital, The University of Melbourne, La Trobe University, Peter MacCallum Cancer Centre, Monash Medical Centre, Monash Health, Murdoch Children's Research Institute, Australasian Leukaemia and Lymphoma Group, Peter MacCallum Cancer Foundation, University of Manitoba, Monash University
ORCID: 0000-0002-5624-0623
Observed ORCID: 0000-0002-5624-0623
OpenAlex ID: A5048715081
A role for pericytes as microenvironmental regulators of human skin tissue regeneration
2009 · Sophie Paquet-Fifield, Holger Schlüter, et al. · Journal of Clinical Investigation · 215
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
2008 · Timothy P. Hughes, Susan Branford, et al. · Blood · 180
PDF
Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
2018 · Rachel Mende, Fabien B. Vincent, et al. · Frontiers in Immunology · 131
PDF
The Australian longitudinal study on male health-methods
2016 · Dianne Currier, Jane Pirkis, et al. · BMC Public Health · 74
PDF
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
2022 · Melissa Northcott, Sarah Jones, et al. · Lupus Science & Medicine · 72
PDF
Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians
2011 · J Grierson, RL Koelmeyer, et al. · HIV Medicine · 63
PDF
Smith-specific regulatory T cells halt the progression of lupus nephritis
2024 · Peter J. Eggenhuizen, Rachel M. Y. Cheong, et al. · Nature Communications · 56
PDF
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
2020 · Rachel Koelmeyer, Hieu Tri Nim, et al. · Lupus Science & Medicine · 56
PDF
Cohort Profile:Ten to Men(the Australian Longitudinal Study on Male Health)
2016 · Jane Pirkis, Dianne Currier, et al. · International Journal of Epidemiology · 49
PDF
Age Matters: Exploring Correlates of Self-Rated Health Across Four Generations of Australian Males
2016 · Rachel Koelmeyer, Dianne Currier, et al. · Behavioral Medicine · 47
PDF
Insulin-like growth factor binding protein-3 (IGFBP-3) localizes to and modulates proliferative epidermal keratinocytes in vivo
2005 · S.R. Edmondson, S.P. Thumiger, et al. · British Journal of Dermatology · 44
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus
2019 · Ai Li Yeo, Rachel Koelmeyer, et al. · Arthritis Care & Research · 38
Analysis of serum B cell‐activating factor from the tumor necrosis factor family ( BAFF ) and its soluble receptors in systemic lupus erythematosus
2019 · Fabien B Vincent, Rangi Kandane‐Rathnayake, et al. · Clinical & Translational Immunology · 34
PDF
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce
2023 · Kathryn Connelly, Laura E. Eades, et al. · Nature Reviews Rheumatology · 31
PDF
HIV futures seven: the health and wellbeing of HIV positive people in Australia
2013 · Grierson, Jeffrey, Pitts, Marian, et al. · Analysis & Policy Observatory · 30
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis
2022 · Tina Ko, Rachel Koelmeyer, et al. · Seminars in Arthritis and Rheumatism · 29
PDF
Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?
2017 · Daniel Boulos, Rachel L Koelmeyer, et al. · Lupus Science & Medicine · 29
PDF
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
2020 · Fabien B Vincent, Rangi Kandane-Rathnayake, et al. · Lupus Science & Medicine · 27
PDF
A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning
2007 · A.P. Grigg, J. Gibson, et al. · Transplantation and Cellular Therapy · 25
PDF
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring
2023 · Ai Li Yeo, Rangi Kandane-Rathnayake, et al. · Lara D. Veeken · 19
The performance of different classification criteria for systemic lupus erythematosus in a real-world rheumatology department
2022 · Brandon C H Tan, Isaac Tang, et al. · Lara D. Veeken · 19
Algorithm for calculating high disease activity in SLE
2021 · Alberta Hoi, Hieu T Nim, et al. · Lara D. Veeken · 15
Disease course following High Disease Activity Status revealed patterns in SLE
2021 · Alberta Hoi, Rachel Koelmeyer, et al. · Arthritis Research & Therapy · 14
PDF
Diabetes in young adult men: social and health-related correlates
2016 · Rachel L. Koelmeyer, Shyamali C. Dharmage, et al. · BMC Public Health · 14
PDF
Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.
2005 · Timothy P. Hughes, Susan Branford, et al. · Blood · 13
Works count: 70
Citation count: 1,392
H-index: 19
I10-index: 26
Year
Topic
Type